Hubungan Nilai Gleason Score dan Grade Groups dengan Ekspresi Fibroblast Activation Protein di Stroma Tumor pada Adenokarsinoma Prostat

Sonny Hardian, Yenita Yenita, Henny Mulyani, Aswiyanti Asri, Etriyel MYH, Husna Yetti

Abstract


Latar Belakang: Gleason score dan grade groups (GrGp) digunakan sebagai nilai prognostik adenokarsinoma prostat. Namun, lingkungan mikro tumor yang didominasi oleh cancer – associated fibroblast (CAF) juga memiliki peranan dalam progresivitas perkembangan kanker dan kejadian metastasis. Terdapat heterogenitas CAF berdasarkan sel asalnya, dan 90% dari CAF bisa dideteksi menggunakan biomarka fibroblast activation protein (FAP). Tujuan: Penelitian ini bertujuan untuk mengetahui hubungan nilai Gleason score dan GrGp dengan ekspresi FAP sebagai biomarka CAF di stroma tumor pada adenokarsinoma prostat. Metode: Penelitian ini adalah penelitian observasional dengan pendekatan cross sectional study. Dilakukan review slide HE dan pulasan IHK dengan antibodi anti-FAP pada 33 sampel blok parafin adenokarsinoma prostat yang berasal dari prostatektomi atau TURP. Hasil pulasan IHK dinilai menggunakan imunnoreactive score (IRS) dengan hasil positif dan negatif. Gleason score dan GrGp dikelompokkan menjadi low grade dan high grade. Analisis data dilakukan dengan Chi-square test dan nilai p <0,05 dianggap bermakna secara stastistik. Hasil: Ekspresi FAP positif ditemukan pada 18 kasus (54,5%) dari 33 sampel yang diperiksa, dengan rincian 50% kasus dikelompok low grade Gleason score dan 54,8% pada high grade Gleason score (p = 1.000). Pada kelompok low GrGp ditemukan 33,3% dan 59,3% pada high GrGp (p = 0,375). Secara statistik tidak didapatkan hubungan bermakna antara nilai Gleason score dan GrGp dengan ekspresi FAP di stroma tumor adenokarsinoma prostat. Kesimpulan: Penelitian ini mendapatkan ekspresi FAP positif dan negatif pada setiap kelompok Gleason score dan GrGp. Hal ini mungkin disebabkan karena adanya heterogenitas dari CAF. Diperlukan penelitian lebih lanjut untuk menilai heterogenitas dari CAF yang berperan dalam adenokarsinoma prostat untuk menggali potensi faktor prognostik dan strategi terapi di masa depan.


Keywords


Adenokarsinoma prostat, cancer – associated fibroblast, fibroblast activation protein, Gleason score, grade groups

Full Text:

PDF

References


. Sutnick AI, Gunawan S. Cancer in Indonesia. Globocan 2020. 2021;360 indonesia.

. Putriyuni A, Oktora MZ, Nurwiyeni N, Tofrizal T. Potential Forkhead Box O 3a as Prognostic Biomarker in Prostate Cancer. Proc 1st Int Conf Heal Sci Biotechnol (ICHB 2021). 2022;47(Ichb 2021):19–23.

. Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Prim [Internet]. 2021;7(1).

. Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365–80.

. Netto GJ, Amin MB, Kench JG. Tumor of the prostate. in : WHO Classification of Tumours Editorial Board. Urinary and male genital tumours [Internet]. 5th ed. Lyon (France): International Agency for Research on Cancer (IARC); 2022.

. Wu Z, Shi J, Lai C, Li K, Li K, Li Z, et al. Clinicopathological significance and prognostic value of cancer-associated fibroblasts in prostate cancer patients. Urol Oncol Semin Orig Investig [Internet]. 2021;39(7):433.e17-433.e23.

. Adamaki M, Zoumpourlis V. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther [Internet]. 2021;228:107932.

. Owen JS, Clayton A, Pearson HB. Cancer-Associated Fibroblast Heterogeneity, Activation and Function: Implications for Prostate Cancer. Biomolecules. 2023;13(1):1–45.

. Boudadi K, Antonarakis ES. Resistance to novel antiandrogen therapies in metastatic castration-resistant prostate cancer. Clin Med Insights Oncol. 2016;10:1–9.

. Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: Cancer-associated fibroblasts and their markers. Int J Cancer. 2020;146(4):895–905.

. Bonollo F, Thalmann GN, Julio MK De, Karkampouna S. The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis. Cancers (Basel). 2020;12(7):1–28.

. Clark KC, Wu Y, Taylor RA, Daly RJ. Novel Therapeutic Targets and Biomarkers Associated with Prostate Cancer-Associated Fibroblasts (CAFs). Crit Rev Oncog. 2022;27(1):1–24.

. Paulsson J, Micke P. Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin Cancer Biol [Internet]. 2014;25:61–8.

. Yusim I, Krenawi M, Mazor E, Novack V, Mabjeesh NJ. The use of prostate specific antigen density to predict clinically significant prostate cancer. Sci Rep [Internet]. 2020;10(1):1–6.

. Rizky Prasetya G, Saraswati M, Rizal AH. Hamid A, BRE. Matondang S. Clinicopathological Profile of Prostate Adenocarcinoma Cases at Cipto Mangunkusumo Hospital in 2010-2019 with Special Overview of Robotic Biopsy. Maj Patol Indones. 2022;31(3):462–70.

. Murtiyani S, S. Hernowo B, Suryanti S. Hubungan CXC Chemokine Receptor 4 (CXCR4) dan Matrix Metalloproteinase 9 (MMP 9) dengan Kemampuan Metastasis Adenokarsinoma Prostat. J Kedokt Yars. 2019;27(1):024–34.

. Nurlaili R, Apriyani N, Saleh MI. Ekspresi alpha methylacyl co-a racemase (amacr) pada adenokarsinoma prostat dan high grade prostatic intraepithelial neoplasia (hgpin). J Kedokt dan … [Internet]. 2017;4(2):76–82.

. Oktavia R. Profil_Histopatologik_Adenokarsinoma_Prostat_di_La. 2017;9(Supplement 1):99–106.

. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63–89.

. Bashir MN. Epidemiology of prostate cancer. Asian Pacific J Cancer Prev. 2015;16(13):5137–41.

. Myint ZW, Sun RC, Hensley PJ, James AC, Wang P, Strup SE, et al. Evaluation of glutaminase expression in prostate adenocarcinoma and correlation with clinicopathologic parameters. Cancers (Basel). 2021;13(9).

. Prendeville S, Nesbitt ME, Evans AJ, Fleshner NE, van der Kwast TH. Variant Histology and Clinicopathological Features of Prostate Cancer in Men Younger than 50 Years Treated with Radical Prostatectomy. J Urol [Internet]. 2017;198(1):79–85.

. Kryvenko ON, Williamson SR, Schwartz LE, Epstein JI. Gleason score 5 + 3 = 8 (grade group 4) prostate cancer—a rare occurrence with contemporary grading. Hum Pathol [Internet]. 2020;97:40–51.

. Huynh MA, Chen MH, Wu J, Braccioforte MH, Moran BJ, D’Amico A V. Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death. Eur Urol [Internet]. 2016;69(6):976–9.

. Knipper S, Preisser F, Mazzone E, Mistretta FA, Tian Z, Briganti A, et al. Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study. Clin Genitourin Cancer [Internet]. 2019;17(3):231-237.e2.

. Patil N, Gaitonde K. Clinical perspective of prostate cancer. Top Magn Reson Imaging. 2016;25(3):103–8.

. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8(12).

. Kessel K, Seifert R, Weckesser M, Boegemann M, Huss S, Kratochwil C, et al. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging. Ann Nucl Med [Internet]. 2022;36(3):293–301.

. Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K, Razmaria A, et al. Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study. J Nucl Med. 2022;63(7):1021–6.

. Ortiz-Otero N, Clinch AB, Hope J, Wang W, Reinhart-King CA, King MR. Cancer associated fibroblasts confer shear resistance to circulating tumor cells during prostate cancer metastatic progression. Oncotarget. 2020;11(12):1037–50.

. Hintz HM, Gallant JP, Vander Griend DJ, Coleman IM, Nelson PS, LeBeau AM. Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography. Clin Cancer Res. 2020;26(18):4882–91.

. Vlachostergios PJ, Karathanasis A, Tzortzis V. Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival. Genes (Basel). 2022;13(1).

. Gerashchenko G V., Grygoruk O V., Kononenko OA, Gryzodub OP, Stakhovsky EO, Kashuba VI. Expression pattern of genes associated with tumor microenvironment in prostate cancer. Exp Oncol. 2018;40(4):315–22.

. Pellinen T, Sandeman K, Blom S, Turkki R, Hemmes A, Välimäki K, et al. Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer. Cancer Res Commun. 2022;2(3):172–81.

. Dmochowska N, Milanova V, Mukkamala R, Chow KK, Pham NTH, Srinivasarao M, et al. Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors. Small. 2023;19(21):1–28.

. Montironi R, Santoni M, Mazzucchelli R, Burattini L, Berardi R, Galosi AB, et al. Prostate cancer: From Gleason scoring to prognostic grade grouping. Expert Rev Anticancer Ther. 2016;16(4):433–40.




DOI: https://doi.org/10.33854/heme.v6i2.1483

Refbacks

  • There are currently no refbacks.


Creative Commons License   Health and Medical Journal This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.